Furthermore, an antibody drug conjugate (ADC) termed Inotuzumab ozogamicin aiming for targeted cytotoxic drug delivery to CD22 expressing B-ALL cells has been proven to be superior to standard therapy in r/r B-ALL [11]. This evidence concerns the gene CD22 and acute lymphoblastic leukemia.